Cannabinoids show limited promise, but major safety gaps remain
Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.
AI Summary
This systematic review examined whether cannabis and cannabinoids can treat mental health and substance use disorders. It included 82 experimental studies and 118 observational studies. Randomized trials found a modest reduction in anxiety symptoms and a possible improvement in PTSD symptoms in one small trial, but the evidence was limited and often indirect. There was no clear benefit for depression, ADHD, psychosis, or Tourette syndrome.
For substance use disorders, one randomized trial found that cannabinoids worsened cannabis use disorder severity, while evidence for alcohol, opioid, and tobacco use disorders was very limited. Observational studies often suggested benefits, but their results were considered unreliable because of a high risk of bias. THC was linked to more withdrawals due to adverse events, and the overall certainty of evidence was predominantly very low. For practical purposes, the findings do not support cannabinoids as first-line treatments, and users should be especially cautious about THC when managing mental health or substance use problems.
š” Key Findings
š
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.